Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.

Sundar Jagannath,Nedra Joseph,Concetta Crivera,Akshay Kharat,Carolyn C Jackson,Satish Valluri,Patricia Cost,Hilary Phelps,Rafal Slowik,Timothy Klein,Lee Smolen,Xueting Yu,Adam D Cohen

Oncology and therapy（2023）

引用 0|浏览2

暂无评分

摘要

Cost estimates from this analysis, which disaggregates CAR-T therapy costs, provide a comprehensive view of the cost components of CAR-T therapy that can help healthcare decision-makers make informed choices regarding the use of cilta-cel. Real-world costs may differ with improved AE prevention and mitigation strategies.

查看译文

关键词

Chimeric antigen receptor T-cell (CAR-T) therapy,Ciltacabtagene autoleucel (cilta-cel),Relapsed/refractory multiple myeloma (RRMM)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要